Nitro-chloromethylbenzindolines: Hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators

Molecular Cancer Therapeutics

Volumn 8, Issue 10, 2009, Pages 2903-2913

  Wilson, William R ^a   Stribbling, Stephen M ^a,b   Pruijn, Frederik B ^a   Syddall, Sophie P ^a   Patterson, Adam V ^a   Liyanage, H D Sarath ^a   Smith, Eileen ^a,c   Botting, K Jane ^a   Tercel, Moana ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Watercare Services Ltd   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DNA; NITRO DERIVATIVE; NITROCHLOROMETHYLBENZINDOLINE DERIVATIVE; NITROREDUCTASE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOTOXICITY; DNA ALKYLATION; DRUG POTENCY; ESCHERICHIA COLI; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TUMOR CELL;

ADENINE; ALKYLATING AGENTS; ALKYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; BYSTANDER EFFECT; CELL CULTURE TECHNIQUES; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; DNA; DNA ADDUCTS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; MICE; NEOPLASMS; NUCLEIC ACID CONFORMATION; PRODRUGS; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350231753     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0571     Document Type: Article

References (50)

1. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009;26:19-34.
2. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-943
3. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680-687 (Pubitemid 34111374)
4. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24.
5. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-447
6. Tatum JL, Kelloff GJ, Gillies RJ, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006;82: 699-757.
7. McKeown SR, Cowen RL, Williams KJ. Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol) 2007;19:427-442
8. Chen Y, Hu L. Design of anticancer prodrugs for reductive activation. Med Res Rev 2009;29:29-64.
9. Wardman P. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. Curr Med Chem 2001;8: 739-761 (Pubitemid 32427904)
10. Plumb JA, Workman P. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity. Int J Cancer 1994;56:134-139 (Pubitemid 24044806)
11. Kim JY, Patterson AV, Stratford IJ, Hendry JH. The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines. Anticancer Drugs 2004;15:71-77
12. Patterson AV, Guise CP, Abbattista M, et al. The bioreductive prodrug PR-104 is activated under aerobic conditions by human aldo-keto reductase 1C3 (prostaglandin F synthase). EJC Supplements 2008;6:473.
13. Hicks KO, Pruijn FB, Secomb TW, et al. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J Natl Cancer Inst 2006;98:1118-1128
14. Phillips RM, Loadman PM, Cronin BP. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer 1998;77:2112-2119
15. Koch CJ. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res 1993;53:3992-3997
16. Lee AE, Wilson WR. Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice. Toxicol Appl Pharmacol 2000;163: 50-59
17. Parmar K, Mauch P, Vergilio J, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007;104:5431-5436 (Pubitemid 47175697)
18. Wilson WR, Hicks KO, Pullen SM, et al. Bystander effects of bioreductive drugs: potential for exploiting pathological tumor hypoxia with dinitrobenzamide mustards. Radiat Res 2007;167:625-636
19. Patterson AV, Ferry DM, Edmunds SJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res 2007;13:3922-3932
20. Hicks KO, Myint H, Patterson AV, et al. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int J Radiat Oncol Biol Phys 2007;69:560-571 (Pubitemid 47380109)
21. Boger DL, Johnson DS. CC-1065 and the duocarmycins: understanding their biological function through mechanistic studies. Angew Chem Int Ed Engl 1996;35:1438-1474 (Pubitemid 26310030)
22. Kobayashi E, Okamoto A, Asada M, et al. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. Cancer Res 1994;54:2404-2410 (Pubitemid 24138732)
23. Pavlidis N, Aamdal S, Awada A, et al. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG). Cancer Chemother Pharmacol 2000;46:167-171 (Pubitemid 30624849)
24. Tercel M, Denny WA, Wilson WR. Nitrogen and sulfur analogues of the seco-CI alkylating agent: synthesis and cytotoxicity. Bioorg Med Chem Lett 1996;6:2735-2740 (Pubitemid 26387257)
25. Atwell GJ, Tercel M, Boyd M, Wilson WR, Denny WA. Synthesis and cytotoxicity of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl) carbonyl]-1,2-dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) and related 5-alkylamino analogues: new DNA minor groove alkylating agents. J Org Chem 1998;63:9414-9420
26. Tercel M, Gieseg MA, DennyWA, Wilson WR. Synthesis and cytotoxicity of amino-seco-DSA: an amino analogue of the DNA alkylating agent duocarmycin SA. J Org Chem 1999;64:5946-5953 (Pubitemid 29383081)
27. Tercel M, Gieseg MA, Milbank JB, et al. Cytotoxicity and DNA interaction of the enantiomers of 6-amino-3-(chloromethyl)-1-[(5,6,7-trimethoxyindol-2-yl) carbonyl]indo-line (amino-seco-CI-TMI). Chem Res Toxicol 1999;12:700-706
28. Gieseg MA, Matejovic J, Denny WA. Comparison of the patterns of DNA alkylation by phenol and amino seco-CBI-TMI compounds: use of a PCR method for the facile preparation of single end-labelled double-stranded DNA. Anticancer Drug Des 1999;14:77-84. (Pubitemid 29237700)
29. Tercel M, Denny WA, Wilson WR. A novel nitro-substituted seco-CI-application as a reductively activated adept prodrug. Bioorg Med Chem Lett 1996;6:2741-2744 (Pubitemid 26387258)
30. Tercel M, Denny WA. Synthesis of nitrogen and sulfur analogues of the seco-CI alkylating agent. J Chem Soc Perkin Trans 1998;Perkin Transactions 1:509-519 (Pubitemid 128759700)
31. Atwell GJ, Milbank JJ, Wilson WR, Hogg A, Denny WA. 5-Amino-1- (chloromethyl)-1,2-dihydro-3H-benz[e]indoles: relationships between structure and cytotoxicity for analogues bearing different DNA minor groove binding subunits. J Med Chem 1999;42:3400-3411 (Pubitemid 29409728)
32. Singleton DC, Li D, Bai SY, et al. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411 (NTR). Cancer Gene Ther 2007;14: 953-967 (Pubitemid 350115355)
33. Tercel M, Wilson WR, Anderson RF, Denny WA. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J Med Chem 1996;39: 1084-1094
34. Twentyman PR, Brown JM, Gray JW, et al. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst 1980;64:595-604.
35. Singleton RS, Guise CP, Ferry DM, et al. DNA crosslinks in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism and cytotoxicity. Cancer Res 2009;69:3884-3891
36. Milbank JB, Tercel M, Atwell GJ, et al. Synthesis of 1-substituted 3-(chloromethyl)-6-aminoindoline (6-amino-seco-CI) DNA minor groove alkylating agents and structure-activity relationships for their cytotoxicity. J Med Chem 1999;42:649-658 (Pubitemid 29110781)
37. Brooks N, McHugh PJ, Lee M, Hartley JA. Alterations in the choice of DNA repair pathway with increasing sequence selective DNA alkylation in the minor groove. Chem Biol 2000;7:659-668
38. De Silva IU, McHugh PJ, Clingen PH, Hartley JA. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000;20:7980-7990 (Pubitemid 30777715)
39. Bergstralh DT, Sekelsky J. Interstrand crosslink repair: can XPFERCC1 be let off the hook? Trends Genet 2008;24:70-76
40. Hinz JM, Tebbs RS, Wilson PF, et al. Repression of mutagenesis by Rad51D-mediated homologous recombination. Nucleic Acids Res 2006; 34:1358-1383
41. Gu Y, Patterson AV, Atwell GJ, et al. Roles of DNA repair and reductase activity in the cytotoxicity of the hypoxia-activated dinitrobenzamide mustard PR-104A. Mol Cancer Ther 2009;8:1714-1723
42. Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997;3:177-182 (Pubitemid 27064702)
43. Denny WA, Wilson WR. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumor cells. J Med Chem 1986;29:879-887
44. Dorie MJ, Brown JM. Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 1993;53: 4633-4636
45. Kiakos K, Sato A, Asao T, et al. DNA sequence-selective adenine alkylation, mechanism of adduct repair, and in vivo antitumor activity of the novel achiral seco-amino-cyclopropylbenz[e]indolone analogue of duocarmycin AS-I-145. Mol Cancer Ther 2007;6:2708-2718 (Pubitemid 350058151)
46. Felip E, Rosell R. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. Expert Rev Mol Diagn 2007;7:261-268 (Pubitemid 46798616)
47. Liu JS, Kuo SR, Beerman TA, Melendy T. Induction of DNA damage responses by adozelesin is Sphase-specific and dependent on active replication forks. Mol Cancer Ther 2003;2:41-47
48. Thompson LH, Hinz JM. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mut Res-Fund Mol Mech Mutagen 2009;668:54-72.
49. Marshall RS, Rauth AM. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Res 1988;48:5655-5659
50. Hicks KO, Pruijn FB, Sturman JR, DennyWA, Wilson WR. Multicellular resistance to tirapazamine is due to restricted extravascular transport: a pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures. Cancer Res 2003;63:5970-5977